<?xml version='1.0' encoding='utf-8'?>
<document id="26449548"><sentence text="Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy." /><sentence text="Polypharmacy is an important issue in the care of older patients with cancer, as it increases the risk of unfavorable outcomes" /><sentence text=" We estimated the prevalence of polypharmacy, potentially inappropriate medication (PIM) use, and drug-drug interactions (DDIs) in older patients with cancer in Korea and their associations with clinical outcomes" /><sentence text="" /><sentence text="This was a secondary analysis of a prospective observational study of geriatric patients with cancer undergoing first-line palliative chemotherapy" /><sentence text=" Eligible patients were older adults (≥70 years) with histologically diagnosed solid cancer who were candidates for first-line palliative chemotherapy" /><sentence text=" All patients enrolled in this study received a geriatric assessment (GA) at baseline" /><sentence text=" We reviewed the daily medications taken by patients at the time of GA before starting chemotherapy" /><sentence text=" PIMs were assessed according to the 2015 Beers criteria, and DDIs were assessed by a clinical pharmacist using Lexi-comp Drug Interactions" /><sentence text=" We evaluated the association between polypharmacy and clinical outcomes including treatment-related toxicity, and hospitalization using logistic regression and Cox regression analyses" /><sentence text="" /><sentence text="In total, 301 patients (median age 75 years; range, 70-93) were enrolled; the most common cancer types were colorectal cancer (28" /><sentence text="9%) and lung cancer (24" /><sentence text="6%)" /><sentence text=" Mean number of daily medications was 4" /><sentence text="7 (±3" /><sentence text="1; range, 0-14)" /><sentence text=" The prevalence of polypharmacy (≥5 medications) was 45" /><sentence text="2% and that of excessive polypharmacy (≥10 medications) was 8" /><sentence text="6%" /><sentence text=" PIM use was detected in 137 (45" /><sentence text="5%) patients" /><sentence text=" Clinically significant DDIs were detected in 92 (30" /><sentence text="6%) patients" /><sentence text=" Polypharmacy was significantly associated with hospitalization or emergency room (ER) visits (odds ratio: 1" /><sentence text="73 [1" /><sentence text="18-2" /><sentence text="55], p &lt; " /><sentence text="01)" /><sentence text=" Neither polypharmacy nor PIM use showed association with treatment-related toxicity" /><sentence text="" /><sentence text="Polypharmacy, PIM use, and potential major DDIs were prevalent in Korean geriatric patients with cancer" /><sentence text=" Polypharmacy was associated with a higher risk of hospitalization or ER visits during the chemotherapy period" /><sentence text="" /><sentence text="This study, which included 301 older Korean patients with cancer, highlights the increased prevalence of polypharmacy in this population planning to receive palliative chemotherapy" /><sentence text=" The prevalence of polypharmacy and excessive polypharmacy was 45" /><sentence text="2% and 8" /><sentence text="6%, respectively" /><sentence text=" The prescription of potentially inappropriate medications (PIMs) was detected in 45" /><sentence text="5% and clinically significant drug-drug interaction in 30" /><sentence text="6% of patients" /><sentence text=" Given the association of polypharmacy with increased hospitalization or emergency room visits, this study points to the need for increased awareness and intervention to minimize polypharmacy in the geriatric cancer population undergoing chemotherapy" /><sentence text=" Moreover, specific criteria for establishing PIMs should be adopted for the treatment of older adults with cancer" /><sentence text="" /></document>